Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522595

Anovulatory Bleeding: Clinical Management and Nursing Considerations-An Updated Review

Khulud Mohammed Saleh Zaybi [(1)] , Mushyirah Ahmed A Hadadi [(2)] , Sabah Shatty Shehan Alonazi [(3)] , Salman Aboud Alharbi [(4)] , Msoaad Hadi Mohmmed Masrahi [(5)] , Abrar Ali Khormi [(6)] , Maram Radhi Alanazi [(7)] , Manar Radi Al-Anzi [(8)] , Fatmah Abdullah Saad Alzaid [(9)] , Maram Moghram Ali Moghram [(10)] , Amal Mohammed Omar Alsebyani [(11)]

(1) Ministry of Health, Saudi Arabia,
(2) Alkarbos Primary Health Care Center,Ministry of Health, Saudi Arabia,
(3) King Khalid Hospital, Hafr Al-Batin,Ministry of Health, Saudi Arabia,
(4) Western Neighborhood Health Center In Al-Rass,Ministry of Health, Saudi Arabia,
(5) Al-Hurrath General Hospital Jazan-Ahad Almasareha,Ministry of Health, Saudi Arabia,
(6) Jazan General Hospital,Ministry of Health, Saudi Arabia,
(7) Khafji General Hospital,Ministry of Health, Saudi Arabia,
(8) Maternity & Children's Hospital In Hafr Al-Batin,Ministry of Health, Saudi Arabia,
(9) The First Health Cluster Al-Sahna Health Center In Al-Dilam,Ministry of Health, Saudi Arabia,
(10) Public Health (Riyadh) ,Ministry of Health, Saudi Arabia,
(11) General Jazan Hospital, Ministry of Health, Saudi Arabia

Abstract

Background: Anovulatory bleeding (AUB-O) is a prevalent form of abnormal uterine bleeding characterized by irregular, unpredictable, and frequently heavy menstrual episodes. It results primarily from dysfunction of the hypothalamic–pituitary–ovarian axis, leading to chronic anovulation, unopposed estrogen exposure, and endometrial instability. The condition affects women across reproductive life stages and significantly impacts quality of life, fertility, and long-term endometrial health.

Aim: This review aims to synthesize current evidence regarding the etiology, clinical presentation, diagnostic approach, and management strategies for anovulatory bleeding, highlighting the multidisciplinary role of nursing, clinical evaluation, and patient education.

Methods: A comprehensive narrative review of clinical guidelines, observational studies, and contemporary literature was conducted, with emphasis on endocrine factors, epidemiology, diagnostic criteria, and therapeutic interventions relevant to the management of AUB-O.

Results: AUB-O arises from physiological or pathological disturbances of ovulation, including PCOS, thyroid dysfunction, hyperprolactinemia, stress, medication effects, and extremes of body weight. Diagnosis requires exclusion of pregnancy and structural causes through detailed history, physical examination, laboratory assessment, and imaging. Management includes hormonal regulation, progestin therapy, combined hormonal contraception, lifestyle modification, ovulation induction for infertility, and surgical interventions when indicated. Early evaluation reduces the risk of anemia, endometrial hyperplasia, and malignancy, while structured patient education enhances adherence and outcomes.

Conclusion: AUB-O is a multifactorial condition requiring timely recognition and individualized clinical management. Integration of hormonal therapy, lifestyle interventions, specialist referral, and patient-centered nursing care is essential for optimizing reproductive and overall health outcomes.

Keywords: Anovulatory bleeding, AUB-O, abnormal uterine bleeding, PCOS, hormonal therapy, endometrial hyperplasia, ovulatory dysfunction.

Introduction

Anovulatory bleeding, clinically referred to as abnormal uterine bleeding due to ovulatory dysfunction (AUB-O), represents a noncyclic menstrual disorder marked by irregular, unpredictable, and often prolonged menstrual episodes.[1] This condition is a major cause of abnormal uterine bleeding (AUB), which is one of the most frequently encountered gynecologic complaints in primary care, affecting up to one-third of women of reproductive age.[2] Women with AUB-O often report heavy menstrual flow, irregular cycle length, and episodes of prolonged bleeding that may significantly impact quality of life, leading to fatigue, iron deficiency, and psychosocial distress. The unpredictability of bleeding can also interfere with daily activities, professional obligations, and sexual health, highlighting the need for early recognition and management. AUB-O is most commonly observed during transitional periods in a woman's reproductive life, particularly during

*Corresponding author e-mail: kaziaby2017@hotmail.com (KHULUD MOHAMMED SALEH ZAYBI).
Receive Date: 07 December 2025, Revise Date: 29 December 2025, Accept Date: 31 December 2025

menarche and perimenopause, when hormonal regulation of the menstrual cycle is less stable. Nevertheless, the disorder can occur at any stage of reproductive life and may persist chronically if left unaddressed. Accurate diagnosis of AUB-O requires a comprehensive evaluation to exclude other structural, systemic, or iatrogenic causes of AUB. This evaluation typically involves a detailed menstrual and medical history, focused physical examination, and, when indicated, laboratory studies to assess hormonal profiles, and imaging such as transvaginal ultrasonography to rule out structural abnormalities. Identifying AUB-O early is essential for initiating targeted therapy, preventing complications such as anemia, and addressing underlying endocrine disorders that may contribute to abnormal bleeding patterns.[3] Effective management of AUB-O necessitates a multidisciplinary approach, with nursing care playing a key role in patient assessment, education, and ongoing support. Nurses are often the first clinicians to identify irregular menstrual patterns and coordinate diagnostic evaluation, ensuring adherence to guidelines for evaluation and management. Through patient education, lifestyle counseling, and close monitoring of therapeutic outcomes, nursing interventions can help optimize both clinical and psychosocial outcomes for women affected by AUB-O.

Etiology

The pathogenesis of anovulatory bleeding is primarily linked to dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, which governs normal ovulatory function.[2] Physiological anovulation commonly occurs during the early reproductive years, when the HPO axis has not fully matured, and during the perimenopausal period, when follicular recruitment may occur prematurely, leading to abnormal luteal phase development. This so-called “luteal out-of-phase” phenomenon results in elevated circulating estradiol levels, which can increase endometrial proliferation and menstrual volume, thereby contributing to irregular and excessive uterine bleeding.[4] Additionally, physiological anovulation may be observed during lactation due to prolactin-mediated suppression of ovulation. Pathological causes of anovulatory bleeding often arise from endocrine disorders that disrupt ovulatory function. Polycystic ovary syndrome (PCOS) is the most frequently implicated pathological condition, characterized by hyperandrogenism, insulin resistance, and chronic anovulation.[5] Other endocrine abnormalities associated with AUB-O include hyperprolactinemia, thyroid dysfunction, primary pituitary disorders, and premature ovarian failure. Systemic factors such as severe caloric restriction, excessive physical activity, and psychological stress can also interfere with normal ovulatory cycles, particularly in women with low body mass index or athletes with relative energy deficiency.[3][6] Pharmacologic agents are notable contributors to ovulatory dysfunction. Antiepileptic drugs such as valproate and lamotrigine can alter endocrine regulation, while antipsychotics—including haloperidol, chlorpromazine, and risperidone—are associated with hyperprolactinemia and subsequent anovulatory bleeding.[7][8][9] Typical antipsychotics more frequently induce hyperprolactinemia compared with atypical agents, underscoring the importance of medication review when evaluating patients with AUB-O. Understanding the multifactorial etiology of anovulatory bleeding is essential for directing appropriate investigations, identifying reversible contributors, and implementing individualized treatment plans that address both hormonal regulation and lifestyle factors.



Fig. 1: Anovulatory Bleeding.

Epidemiology

Abnormal uterine bleeding is a prevalent gynecologic disorder, with studies in the United States reporting an annual incidence of approximately 53 cases per 1,000 women of reproductive age.[10] Among the causes of AUB, anovulatory bleeding becomes the predominant etiology once regular menstruation is established, particularly outside the adolescent and perimenopausal windows.[11] The reported prevalence of anovulation varies widely, ranging from 3.4% to 18.6% of menstruating women depending on diagnostic criteria and assessment methods employed.[12] This variability reflects differences in hormonal assessment, cycle monitoring, and population characteristics, highlighting the need for standardized approaches in both clinical practice and research. Certain populations are at higher risk for developing AUB-O. Perimenarchal girls and perimenopausal women are particularly susceptible due to the inherent instability of the HPO axis during these transitional periods. Metabolic factors also influence risk, with obesity recognized as an independent contributor to anovulatory cycles, likely due to insulin resistance and associated endocrine disturbances.[2][3][5][13] Conversely, women with extremely low body mass index, including individuals with anorexia nervosa or high-performance athletes

experiencing relative energy deficiency, are at risk due to suppressed gonadotropin-releasing hormone (GnRH) pulsatility and impaired follicular development.[14] The high prevalence and diverse etiologies of anovulatory bleeding necessitate a proactive clinical approach. Recognizing at-risk populations allows clinicians to implement early screening and diagnostic evaluation, ultimately improving patient outcomes. Nurses play a pivotal role in identifying abnormal menstrual patterns, facilitating laboratory assessments, and coordinating referrals to endocrinology or gynecology specialists. Education on lifestyle modification, weight management, and medication adherence is essential to prevent recurrence and reduce complications. Laboratory services, including hormonal assays, support accurate diagnosis and monitoring, while health administrators ensure that resources, protocols, and clinical pathways are in place to provide comprehensive, timely care for patients experiencing AUB-O. This multidimensional understanding of epidemiology, etiology, and clinical presentation supports a holistic approach to AUB-O, integrating patient-centered nursing care, laboratory evaluation, health system coordination, and public health awareness to optimize outcomes and reduce the burden of abnormal uterine bleeding in reproductive-aged women.

Pathophysiology

The pathophysiology of anovulatory bleeding is closely linked to disruption of normal ovarian follicular development and hormonal regulation within the hypothalamic-pituitary-ovarian (HPO) axis. The ovarian follicle functions as the primary unit for both gametogenesis and steroid hormone production, with its maturation culminating at the midpoint of the ovulatory cycle. Normally, increasing estradiol levels from the developing follicle trigger a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary, inducing ovulation. Post-ovulation, the remnant follicular cells form the corpus luteum, which secretes progesterone to stabilize the endometrium and prepare it for potential implantation. In cases of anovulation, ovulation fails to occur, preventing corpus luteum formation. This results in insufficient progesterone production, leaving the endometrium in a prolonged proliferative state that is unstable and susceptible to irregular, excessive shedding, clinically manifesting as heavy and unpredictable bleeding.[11] High levels of estrogen unopposed by progesterone play a central role in the abnormal endometrial environment seen in AUB-O. Unopposed estrogen contributes to increased endometrial vascular fragility and reduced vascular tone, which intensifies menstrual blood loss. Moreover, alterations in local biochemical mediators further exacerbate abnormal bleeding. Dysregulated prostaglandin synthesis and upregulation of prostaglandin receptors promote excessive vasodilation and uterine contractility, while heightened fibrinolytic activity, including elevated tissue plasminogen activator levels, enhances clot degradation, leading to heavier and prolonged bleeding episodes.[11] Clinically, these pathophysiologic mechanisms manifest as prolonged or heavy menstrual flow, irregular cycle intervals, and intermenstrual bleeding, often causing significant functional and psychological burden for affected women. The combination of hormonal imbalance, vascular instability, and dysregulated endometrial tissue response underscores the complexity of AUB-O, emphasizing the need for a multidisciplinary approach in diagnosis and management, including careful evaluation by nursing staff, laboratory assessment of hormonal profiles, and coordinated clinical interventions to prevent complications such as anemia and reduced quality of life.[2][3][15]

History and Physical

A comprehensive history and physical examination are foundational in the evaluation of anovulatory bleeding and can substantially narrow the differential diagnosis of abnormal uterine bleeding (AUB), guiding the selection of appropriate laboratory testing and imaging. The clinical approach should be tailored according to the patient's age, reproductive status, and presenting symptoms. For adolescent patients, it is crucial to obtain the history both in the presence of parents and privately with the patient to facilitate disclosure of sensitive information, including sexual activity, menstrual irregularities, and psychosocial stressors. This approach ensures that accurate information is obtained while maintaining patient confidentiality and fostering trust. Anovulatory bleeding typically presents as irregular uterine bleeding characterized by prolonged episodes of amenorrhea interspersed with heavy or unpredictable bleeding. Premenstrual symptoms commonly associated with ovulatory cycles, such as breast tenderness, bloating, or cyclic cramping, are usually absent in AUB-O. The condition should be suspected in women presenting with irregular or unpredictable bleeding patterns, particularly at the extremes of reproductive age, such as adolescents and perimenopausal women. Understanding the parameters of a normal menstrual cycle is essential to identifying abnormalities. The expected cycle interval ranges from 21 to 45 days, with menstruation lasting up to seven days and average daily usage of three to six pads or tampons.[16][17] A detailed bleeding history is critical. Frequency, regularity, duration, and volume of menstrual flow should be assessed, recognizing that patient-reported blood loss may be unreliable.[18][19] Questions regarding the passage of clots, frequency of pad or tampon changes, degree of saturation, and the need for overnight protection provide a practical measure of menstrual blood loss. Clinicians should also assess for postcoital bleeding, which may indicate cervical lesions, and for bleeding associated with bowel movements, which could

suggest gastrointestinal sources. Additional systemic symptoms, including fever, pelvic pain, vaginal discharge, and bowel or bladder dysfunction, should be explored, as these may suggest infectious or structural etiologies.

Identification of clinical features associated with specific causes of ovulatory dysfunction is also important. Patients with polycystic ovary syndrome (PCOS) may exhibit obesity, male-pattern or worsening hirsutism, acne, and acanthosis nigricans. Thyroid dysfunction can present with palpitations, thermoregulatory intolerance, fatigue, and weight changes, whereas hyperprolactinemia may manifest as galactorrhea. A history suggestive of coagulopathy, including easy bruising, frequent nosebleeds, or family history of bleeding disorders, should also be elicited. A complete sexual history, including date of last intercourse, number of sexual partners, contraceptive use, prior sexually transmitted infection exposure, and abnormal cervical screening results, is essential. Medical and surgical history, including prior medications, supplements, and gynecologic or abdominal procedures, must be documented. Family history of menstrual irregularities, bleeding disorders, or hormone-sensitive malignancies further informs risk assessment.[3][20][21][22][23] Physical examination is equally critical for evaluating anovulatory bleeding. Vital signs, including orthostatic measurements, should be assessed to detect hypovolemia or anemia. General assessment should include body mass index and body composition. Head and neck examination may reveal pallor indicative of anemia or thyroid abnormalities. Abdominal inspection should assess for tenderness, masses, or distension. A thorough pelvic examination, including evaluation of the vulva, speculum inspection, Pap smear, and cervical cultures if indicated, is essential to identify local structural or infectious causes. Rectal examination may be performed if a gastrointestinal source of bleeding is suspected. Collectively, a thorough history and physical examination not only assist in diagnosing AUB-O but also help exclude structural, infectious, and systemic conditions, guiding further diagnostic workup and management strategies.[3][20][21]

Evaluation

The evaluation of anovulatory bleeding (AUB-O) requires a systematic and stepwise approach to accurately identify the underlying etiology while ruling out conditions that may require urgent intervention. The process begins with a general assessment of abnormal uterine bleeding. If the history or physical examination raises suspicion for a specific pathology, targeted testing should be conducted immediately. At a minimum, all patients should undergo a pregnancy test, either blood or urine, to exclude gestational causes of bleeding, such as miscarriage or ectopic pregnancy. A complete blood count (CBC) is essential, particularly for patients reporting heavy menstrual bleeding, fatigue, dizziness, shortness of breath, lightheadedness, or pica, as these may indicate anemia or thrombocytopenia. In women with recent pregnancy or miscarriage, a quantitative beta-human chorionic gonadotropin (β-hCG) measurement is indicated to exclude gestational trophoblastic disease.[21] After pregnancy is ruled out and anemia is either excluded or addressed, evaluation shifts to identifying underlying causes based on the patient's history, family history, and physical examination. Laboratory testing should be guided by suspected conditions. For thyroid dysfunction, serum thyroid-stimulating hormone (TSH) measurement is indicated. Hyperprolactinemia is evaluated with a serum prolactin level. Assessment for polycystic ovary syndrome (PCOS) includes measuring 17-hydroxyprogesterone, total and free testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and performing a pelvic ultrasound to assess ovarian morphology. Suspected coagulopathies require more extensive testing, including CBC, prothrombin time, partial thromboplastin time, von Willebrand factor antigen, factor VIII levels, and platelet aggregation studies. Positive findings from these investigations guide therapy tailored to the specific etiology, whereas patients without concerning findings or identifiable pathology may be managed with empiric medical therapy.[3][20][22][24]

Age-specific considerations are essential in evaluating AUB-O. Adolescents, from menarche to age 18, typically have low concern for endometrial hyperplasia. Persistent anovulatory cycles beyond two years warrant endometrial biopsy to exclude hyperplasia. Approximately 50% of adolescent girls presenting with heavy menstrual bleeding may have an underlying bleeding disorder, emphasizing the importance of screening for platelet dysfunction and other hematologic conditions, including leukemia, idiopathic thrombocytopenic purpura, and hypersplenism. Women aged 19 to 39 are more likely to have hyperandrogenic chronic anovulation, such as in PCOS, affecting 6% to 10% of this population. Endometrial biopsy is recommended for those who do not respond to medical therapy. Women aged 40 and older, particularly those above 45 or with a concerning personal or family history, should undergo endometrial biopsy as first-line testing to rule out malignancy or hyperplasia.[3][20][22][24] In acute presentations of AUB, defined by sudden episodes of bleeding requiring immediate medical attention, stabilization of the patient takes precedence. Once stabilized, imaging should be employed to identify underlying pathology. Transvaginal ultrasonography serves as the primary modality to evaluate uterine and endometrial structures. Sonohysterography can further delineate endometrial abnormalities. Additional imaging options include hysteroscopy, magnetic resonance imaging (MRI), and saline infusion sonohysterography, particularly in cases unresponsive to medical management or where structural lesions are suspected. Imaging not only confirms structural or

endometrial pathology but also assists in guiding subsequent management strategies, whether medical, procedural, or surgical.[3] A structured evaluation combining history, physical examination, laboratory testing, age-specific guidelines, and judicious use of imaging allows clinicians to systematically identify the cause of AUB-O. Early and accurate evaluation reduces complications, guides appropriate therapy, and improves patient outcomes.

Treatment / Management

Management of anovulatory bleeding (AUB-O) requires a comprehensive and individualized approach that prioritizes the identification and correction of underlying pathophysiological disturbances. The therapeutic strategy is guided by the patient's reproductive goals, the presence of endocrine or metabolic disorders, and the risk of complications such as endometrial hyperplasia or malignancy. Addressing contributory factors, including hormonal imbalances, metabolic derangements, psychological stress, and lifestyle-related causes, is essential. In patients with eating disorders or significant stress-induced anovulation, normalization of nutritional intake and stress reduction are recommended, although these interventions may be challenging to achieve in practice. Similarly, if medications are implicated in ovulatory dysfunction, clinicians should counsel patients regarding the purpose and benefits of the drug, potential alternatives, and mitigation strategies to minimize disruption of ovulatory function. Prioritizing patient safety is paramount, given that prolonged anovulation without intervention can result in excessive endometrial proliferation, increasing the risk of malignancy.[3] Pharmacological interventions remain the mainstay of treatment for AUB-O, particularly when immediate restoration of endometrial protection is required. Progestin therapy can be administered in various formulations, including oral preparations, intramuscular injections, and intrauterine devices (IUDs), and can be employed cyclically to induce regular withdrawal bleeding. The levonorgestrel-releasing intrauterine system is widely applicable across age groups and provides both contraceptive benefits and endometrial protection. Combined hormonal contraception, available as oral pills, transdermal patches, or vaginal rings, offers an alternative means of regulating menstrual cycles while mitigating the risk of endometrial hyperplasia. These regimens are particularly beneficial for patients who do not desire fertility, as they improve cycle regularity and provide effective endometrial protection. For patients actively pursuing conception, temporary use of hormonal therapies may be utilized to stabilize cycles until fertility-focused interventions are initiated.[25]

Lifestyle modification and correction of underlying metabolic disturbances are central to fertility-focused management, particularly in patients with polycystic ovary syndrome (PCOS). Weight reduction, even as modest as a 5% decrease in body mass, has been shown to lower circulating androgen levels and facilitate the spontaneous resumption of ovulatory cycles. Pharmacological agents that promote weight loss, such as orlistat and sibutramine, may also support improved ovarian function in selected patients.[25] Ovulation induction represents a cornerstone in the management of anovulatory infertility. Traditionally, clomiphene citrate has been the first-line agent, achieving live birth rates ranging from 20% to 40% over six months, depending on patient characteristics. Higher doses may be required in some patients to achieve ovulation.[26][27] However, emerging evidence indicates that letrozole may offer superior efficacy in PCOS, demonstrating higher clinical pregnancy and live birth rates compared with clomiphene.[28] The use of insulin-sensitizing agents, such as metformin, particularly in obese patients, can further enhance ovulatory response and improve pregnancy outcomes when combined with clomiphene therapy.[29] Surgical interventions are reserved for patients in whom medical management is ineffective or contraindicated. Laparoscopic ovarian drilling may be considered for patients with PCOS resistant to ovulation induction; however, current evidence does not conclusively demonstrate improvements in live birth or clinical pregnancy rates, and concerns persist regarding long-term ovarian function. Some studies suggest that the procedure may reduce the risk of multiple gestations. In morbidly obese patients with PCOS, bariatric surgery has demonstrated normalization of both reproductive and metabolic parameters.[30][31]

Endometrial sampling is critical in mitigating the risk of hyperplasia and malignancy. Women aged 45 and older, or younger women with unopposed estrogen exposure, persistent bleeding, or failure of medical therapy, should undergo endometrial biopsy or dilation and curettage.[11] For patients who have completed childbearing, hysterectomy represents the definitive treatment for refractory AUB and provides permanent resolution of hyperplasia risk.[3] Endometrial ablation offers a less invasive alternative, effectively reducing menstrual bleeding, though it is contraindicated in cases of endometrial hyperplasia or malignancy. Long-term follow-up is necessary, as a proportion of patients may require subsequent hysterectomy due to treatment failure or persistent abnormal bleeding. Studies report one-year treatment success rates of 88.3% for radiofrequency endometrial ablation and 81.7% for resectoscopic endometrial resection, with amenorrhea rates of 41% and 35%, respectively. Over extended follow-up, approximately 13.4% of patients undergoing ablation eventually required hysterectomy, emphasizing the need for careful patient selection and counseling.[32][33][34][35] In summary, effective management of AUB-O necessitates an individualized approach that integrates lifestyle modification,

pharmacological therapy, fertility-focused interventions, and surgical options when indicated. Continuous monitoring, risk mitigation for endometrial pathology, and alignment with patient-specific reproductive goals are essential to optimize outcomes and ensure patient safety.

Differential Diagnosis

Anovulatory bleeding (AUB-O) is fundamentally a diagnosis of exclusion, requiring the systematic elimination of alternative causes of abnormal uterine bleeding. The International Federation of Gynecology and Obstetrics (FIGO) established the PALM-COEIN classification system in 2011 to standardize the categorization of abnormal uterine bleeding in nonpregnant women. This framework divides causes into structural (PALM) and nonstructural (COEIN) etiologies, facilitating both diagnostic clarity and management planning. Structural causes—polyps, adenomyosis, leiomyomas, and malignancy—are typically identifiable through imaging or histopathological evaluation and may necessitate surgical intervention. In contrast, nonstructural causes, including coagulopathies, ovulatory dysfunction, endometrial disorders, iatrogenic factors, and entities not yet classified, are predominantly managed through medical therapies.[36] Beyond uterine-specific pathologies, extrauterine sources of bleeding such as vaginitis, genital trauma, foreign bodies, vulvar lesions, and vaginal neoplasms must be considered in the differential diagnosis to prevent misattribution of symptoms to ovulatory dysfunction.[3][5] Specific etiologies of ovulatory dysfunction should be carefully assessed. Pregnancy-related causes, including uncomplicated gestation, threatened or incomplete miscarriage, and ectopic gestation, must be ruled out. Physiologic anovulation is common during menarche and perimenopause, while premature ovarian failure can also precipitate irregular bleeding. Lactation-induced anovulation and endocrine disturbances, including thyroid dysfunction, hyperprolactinemia, and pituitary disorders, contribute significantly to irregular menses. Medication-induced ovulatory dysfunction is another important consideration, with agents such as antipsychotics, tricyclic antidepressants, selective serotonin reuptake inhibitors, verapamil, and antiemetics exerting potential effects on the hypothalamic-pituitary-ovarian axis. Accurate identification of these contributing factors informs both prognosis and targeted therapeutic interventions.[3][36]

Prognosis

The overall prognosis for patients diagnosed with AUB-O is generally favorable, particularly when the condition is identified and managed in a timely manner. Medical management frequently results in substantial symptomatic improvement, leading to enhanced quality of life and reduced morbidity associated with chronic abnormal uterine bleeding.[20] Early diagnosis and treatment are particularly important to prevent long-term sequelae, including endometrial hyperplasia and malignancy, which may develop secondary to prolonged unopposed estrogen exposure. Although these complications are serious, outcomes for endometrial carcinoma are relatively favorable compared with other gynecologic malignancies, especially when detected early. Fertility outcomes in patients with AUB-O are also promising. Ovulation induction with pharmacologic agents has demonstrated efficacy in restoring reproductive function, with recent studies indicating higher live birth rates with letrozole (27.5%) compared to clomiphene citrate (19.1%).[37]

Complications

Complications arising from anovulatory bleeding primarily reflect the consequences of chronic unopposed estrogen exposure and irregular menses. Infertility is one of the most frequent complications, necessitating ovulation induction or referral to reproductive endocrinology when conception is desired. Chronic anovulation increases the risk of endometrial hyperplasia and, in some cases, endometrial carcinoma, necessitating patient education regarding these risks when formulating treatment plans.[3] Excessive menstrual blood loss may lead to iron-deficiency anemia, which requires careful assessment and management through oral or intravenous iron supplementation. For patients utilizing oral contraceptives, modification of the regimen, such as skipping placebo intervals, may be advised to minimize blood loss. Rarely, procedures such as endometrial ablation carry risks including pituitary infarction (Sheehan syndrome), underscoring the importance of pre-procedural counseling and informed consent.[3]

Consultations

The role of specialty care is integral in the timely diagnosis and management of AUB-O. While most cases can be effectively addressed in primary care, referral to a gynecologist is indicated in the presence of structural uterine pathology or when surgical management is contemplated. Obstetric and gynecological consultation is also warranted for patients pursuing fertility, ensuring the application of specialized ovulation induction techniques. In cases where bleeding disorders are suspected, hematology-oncology consultation is appropriate to facilitate comprehensive evaluation and management.[3][24]

Patient Education

Preventive measures and patient education are critical components of managing AUB-O. Patients should be counseled on maintaining a healthy body weight, as obesity is an independent risk factor for chronic anovulation.[3][38] Education regarding normal menstrual physiology during menarche and perimenopause can alleviate anxiety and promote timely medical evaluation for abnormal bleeding. Clear communication regarding what constitutes physiologic versus pathologic menstrual patterns empowers patients to recognize concerning

symptoms, facilitating early intervention. Timely management reduces the risk of complications associated with prolonged abnormal uterine bleeding and enhances overall reproductive and general health outcomes.

Other Issues

Key clinical insights support the effective recognition and management of AUB-O. Anovulation may be physiological at the extremes of reproductive age, and careful history-taking and physical examination are essential to differentiate it from other causes of abnormal uterine bleeding. In adolescents, obtaining history both in the presence and absence of parents enhances diagnostic accuracy. As a diagnosis of exclusion, AUB-O should only be established after other potential etiologies have been systematically ruled out. Management typically involves hormonal therapy, either through combined oral contraceptives or progestin-only preparations, with the levonorgestrel-releasing intrauterine device demonstrating superior efficacy in controlling heavy menstrual bleeding. Understanding these principles ensures optimal patient outcomes and minimizes long-term complications associated with this condition.

Enhancing Healthcare Team Outcomes

The management of AUB-O benefits significantly from a coordinated interprofessional approach. Primary care clinicians and nurses often serve as the first point of contact, emphasizing the importance of timely referral to gynecologic specialists to expedite evaluation and management. Lifestyle counseling, including guidance on nutrition, exercise, smoking cessation, and weight management, is an essential component of care that can be provided in primary care settings. Pharmacists contribute by assisting with medication selection, dose optimization, drug interaction monitoring, and patient education. Nursing staff play a pivotal role in administering therapies, monitoring response, and addressing patient concerns. Effective communication among all members of the healthcare team is crucial to ensure cohesive management, optimize therapeutic outcomes, and enhance patient quality of life.[39][40][41]

Conclusion:

Anovulatory bleeding represents a complex gynecologic disorder with significant clinical and psychosocial implications. Because it is fundamentally a diagnosis of exclusion, accurate evaluation relies on comprehensive history-taking, physical examination, and careful selection of laboratory and imaging studies. Early recognition is essential, as prolonged anovulation exposes patients to unopposed estrogen stimulation, increasing the risk of endometrial hyperplasia, infertility, and chronic anemia. The condition's multifactorial nature—spanning endocrine imbalances, metabolic disturbances, medication effects, and lifestyle factors—requires an individualized and holistic approach. Effective management integrates hormonal therapies, such as progestins and combined contraceptives, alongside lifestyle modifications targeting weight management and metabolic health. For women seeking fertility, ovulation induction with agents like letrozole or clomiphene can achieve favorable outcomes. In cases refractory to medical treatment, surgical approaches, including endometrial sampling, ovarian drilling, or hysterectomy, may be warranted based on patient age, risk profile, and reproductive goals. A coordinated interprofessional strategy is crucial: primary care providers, gynecologists, nurses, and pharmacists each contribute to accurate diagnosis, patient education, treatment adherence, and monitoring. Empowering patients through counseling on normal menstrual patterns, risk factors, and when to seek medical care further enhances outcomes. Ultimately, a patient-centered, multidisciplinary approach ensures optimal long-term reproductive and overall health for individuals affected by AUB-O.

References:

1. Fraser IS, Hickey M, Song JY. A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception. Hum Reprod. 1996 Oct;11 Suppl 2:165-78.
2. Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update. 2002 Jan-Feb;8(1):60-7.
3. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-185.
4. Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause. 2009 Jan-Feb;16(1):50-9.
5. Munro MG, Critchley HO, Broder MS, Fraser IS., FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011 Apr;113(1):3-13.
6. Hamilton-Fairley D, Taylor A. Anovulation. BMJ. 2003 Sep 06;327(7414):546-9.
7. Morrell MJ, Hayes FJ, Sluss PM, Adams JM, Bhatt M, Ozkara C, Warnock CR, Isojärvi J. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol. 2008 Aug;64(2):200-11.
8. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics--a review. Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97.

9. Worly BL, Gur TL. The effect of mental illness and psychotropic medication on gametes and fertility: a systematic review. J Clin Psychiatry. 2015 Jul;76(7):974-85.
10. Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: findings from the National Health Interview Survey, 1984 to 1992. Am J Public Health. 1996 Feb;86(2):195-9.
11. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012 Jul;120(1):197-206.
12. Lynch KE, Mumford SL, Schliep KC, Whitcomb BW, Zarek SM, Pollack AZ, Bertone-Johnson ER, Danaher M, Wactawski-Wende J, Gaskins AJ, Schisterman EF. Assessment of anovulation in eumenorrheic women: comparison of ovulation detection algorithms. Fertil Steril. 2014 Aug;102(2):511-518.e2.
13. Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest. 1975 Apr;55(4):699-706.
14. Mu L, Zhao Y, Li R, Lai Y, Chang HM, Qiao J. Prevalence of polycystic ovary syndrome in a metabolically healthy obese population. Int J Gynaecol Obstet. 2019 Aug;146(2):164-169.
15. Aksel S, Wiebe RH, Tyson JE, Jones GS. Hormonal findings associated with aluteal cycles. Obstet Gynecol. 1976 Nov;48(5):598-602.
16. Itriyeva K. The normal menstrual cycle. Curr Probl Pediatr Adolesc Health Care. 2022 May;52(5):101183.
17. Committee Opinion No. 651 Summary: Menstruation in Girls and Adolescents: Using the Menstrual Cycle as a Vital Sign. Obstet Gynecol. 2015 Dec;126(6):1328.
18. Haynes PJ, Hodgson H, Anderson AB, Turnbull AC. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol. 1977 Oct;84(10):763-8.
19. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol. 1984 Aug 01;149(7):788-93.
20. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016 Jan;214(1):31-44.
21. Wouk N, Helton M. Abnormal Uterine Bleeding in Premenopausal Women. Am Fam Physician. 2019 Apr 01;99(7):435-443.
22. Elmaoğulları S, Aycan Z. Abnormal Uterine Bleeding in Adolescents. J Clin Res Pediatr Endocrinol. 2018 Jul 31;10(3):191-197.
23. Kızılcan Çetin S, Aycan Z, Özsu E, Şıklar Z, Ceran A, Erişen Karaca S, Şenyazar G, Berberoğlu M. Evaluation of Abnormal Uterine Bleeding in Adolescents: Single Center Experience. J Clin Res Pediatr Endocrinol. 2023 Aug 23;15(3):230-237.
24. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785. Obstet Gynecol. 2019 Sep;134(3):e71-e83.
25. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018 Jun;131(6):e157-e171.
26. Vyrides AA, El Mahdi E, Giannakou K. Ovulation induction techniques in women with polycystic ovary syndrome. Front Med (Lausanne). 2022;9:982230.
27. Horowitz E, Weissman A. The stair-step approach in treatment of anovulatory PCOS patients. Ther Adv Reprod Health. 2020 Jan-Dec;14:2633494120908818
28. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014 Feb 24;(2):CD010287.
29. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol. 2008 Apr;111(4):959-68.
30. Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD001122.
31. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005 Dec;90(12):6364-9.
32. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 81, May 2007. Obstet Gynecol. 2007 May;109(5):1233-48.
33. Wortman M, Vilos GA, Vilos AG, Abu-Rafea B, Dwyer W, Spitz R. Postablation Endometrial Carcinoma. JSLS. 2017 Apr-Jun;21(2)
34. Cooper J, Gimpelson R, Laberge P, Galen D, Garza-Leal JG, Scott J, Leyland N, Martyn P, Liu J. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):418-28.
35. Shavell VI, Diamond MP, Senter JP, Kruger ML, Johns DA. Hysterectomy subsequent to endometrial ablation. J Minim Invasive Gynecol. 2012 Jul-Aug;19(4):459-64.

36. Achanna KS, Nanda J. Evaluation and management of abnormal uterine bleeding. Med J Malaysia. 2022 May;77(3):374-383.
37. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H., NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014 Jul 10;371(2):119-29.
38. Wise MR, Gill P, Lensen S, Thompson JM, Farquhar CM. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am J Obstet Gynecol. 2016 Nov;215(5):598.e1-598.e8.
39. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J., ECLIPSE Trial Collaborative Group. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013 Jan 10;368(2):128-37.
40. Busfield RA, Farquhar CM, Sowter MC, Lethaby A, Sprecher M, Yu Y, Sadler LC, Brown P, Johnson N. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG. 2006 Mar;113(3):257-63.
41. Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011 Jan;83(1):48-54.

.